BioSpace News Archive

OKYO Pharma Limited announced that it has received clearance of its Investigational New Drug application from the U.S. Food and Drug Administration to initiate a Phase 2, first-in-human, clinical study of OK-101 for the treatment of DED.

IASO Biotherapeutics announced that the Investigational New Drug application for its in-house developed BCMA CAR-T CT103A has been approved by the U.S. Food and Drug Administration for use in U.S. clinical trials for relapsed/refractory multiple myeloma.

ProKidney Corp. today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare Conference in San Francisco on Wednesday, January 11th, 2023, at 3:45 PM PT.

AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM) Initiation of AFM28 clinical development in the first half of 2023 on track.

Pluri Inc., a leading biotechnology Company, issued the following update to shareholders from CEO and President Yaky Yanay and announced that as planned the Company’s joint venture with Tnuva Group has successfully achieved proof of concept in its development of cultivated meat based on Pluri’s proprietary 3D cell-based technology platform.

Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with its six-month, Phase 2b, placebo-controlled clinical trial of Xanamem in patients with early stages of Alzheimer’s Disease (AD).

Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released the second “Conversations” video podcast, featuring a virtual fireside discussion with neuroscience experts who share their perspective on clinical data recently presented at the 2022 CTAD conference in San Francisco, and implications for future Alzheimer’s disease,

AIkido Pharma Inc. (NASDAQ: AIKI) (the “Company”) today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from “AIKI” to “DOMH.”

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules are available in the U.S. by prescription for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.